产品介绍

Vitronectin和纤溶酶原激活物抑制剂1型是在循环系统和细胞周围区域相互作用以调节纤维蛋白溶解、细胞粘附和迁移的蛋白质。纤溶酶原激活物抑制剂1型，一种丝氨酸蛋白酶，通过与血浆蛋白玻连蛋白结合，影响止血过程的关键调节因素，例如血栓形成和伤口愈合。此外，在肿瘤转移等事件中，玻连蛋白和纤溶酶原激活物抑制剂1型复合物调节血小板和细胞与细胞外基质的结合。玻连蛋白的血浆浓度为200至400μg/ml。由经美国食品药品监督管理局要求的测试显示对HBsAg、抗-HCV、抗-HBc无反应且对抗-HIV 1和2呈阴性的血浆制备。Vitronectin and plasminogen activator inhibitor type 1 are proteins that interact in the circulatory system and pericellular region to regulate fibrinolysis, cell adhesion, and migration. Plasminogen activator inhibitor type 1, a serine proteinase, through its binding to the plasma protein vitronectin, influences processes that are key regulators of hemostatic process, for example, thrombosis and wound healing. In addition the vitronectin and plasminogen activator inhibitor type 1 complex regulates binding of blood platelets and cells to extracellular substrata in events like tumor metastasis. The plasma concentration of vitronectin is 200 to 400 μg/ml.  Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.  Product Citation:Wihadmadyatami H, Röder L, Berghöfer H, Bein G, Heidinger K, Sachs UJ, Santoso S. Immunisation against IIb3 and v3 in a type 1 variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on 3. Thromb Haemost. 2016 Aug 1;116(2):262-71. doi: 10.1160/TH15-12-0982. Epub 2016 Apr 21.